Whalesbook
Login Sign Up
Home Market News Corporate News Pricing Contact Us

Bal Pharma to Issue Warrants to Promoter, Raise ₹8.1 Cr

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Bal Pharma to Issue Warrants to Promoter, Raise ₹8.1 Cr

Bal Pharma plans to issue 10 lakh convertible warrants to promoter Shailesh Siroya, raising ₹8.1 crore. Funds will support a new API facility in Karnataka. Shareholder approval is pending via postal ballot.

Bal Pharma to Issue Warrants to Promoter

Bal Pharma Limited proposes to issue 1,000,000 convertible warrants to its promoter, Mr. Shailesh Siroya, aiming to raise ₹8.1 crore. The company is seeking shareholder approval for this preferential issue through a postal ballot.

What just happened

Bal Pharma announced a plan to issue 1,000,000 convertible warrants to promoter Mr. Shailesh Siroya at ₹81 per warrant, totaling ₹8.1 crore. This requires shareholder approval via postal ballot.

Why this matters

The funds will help establish a new greenfield API manufacturing facility in Yadagiri, Karnataka, supporting the company's growth beyond ₹300 crore revenue. It also increases promoter holding to 53.76%.

The backstory

Bal Pharma has crossed the ₹300 crore revenue mark and aims for expansion. The company has acquired land and obtained environmental clearances for the new API facility.

What changes now

Upon conversion, promoter shareholding will increase. The capital raised will fund a significant expansion project, a key driver for future revenue.

Risks to watch

Delays in project execution or failure to convert warrants within 18 months could impact growth plans.

Peer comparison

While specific peer data isn't provided in the filing, API manufacturing expansion is a common strategy for pharmaceutical companies seeking to strengthen their value chain and improve margins.

Context metrics

  • Issue Price: ₹81 per warrant (₹71 premium)
  • Total Funds Raised: ₹8.1 crore
  • Warrant Tenure: 18 months
  • Promoter Shareholding: Expected increase from 50.85% to 53.76%

What to track next

Monitor shareholder approval via postal ballot and the progress of the greenfield API facility construction and commissioning.

Reader Takeaway: Promoter confidence and capacity expansion funded by capital raise; project execution and warrant conversion are key.

Disclaimer:This article is published for informational purposes only. While reasonable efforts are made to ensure accuracy, completeness, and timeliness, readers are encouraged to independently verify information before making any decisions based on the content. The views and information presented are subject to editorial review and may be updated without notice.